Cetuximab in NSCLC: Another trial needed

The Lancet Oncology

Volumn 12, Issue 1, 2011, Pages 3-4

  Perrone, Francesco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ADVANCED CANCER; CANCER SURVIVAL; DRUG EFFECT; DRUG ERUPTION; DRUG RESPONSE; GENE MUTATION; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS;

ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; EXANTHEMA; HUMANS; LUNG NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 78650700834     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70289-8     Document Type: Letter

References (5)

1. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
2. Questions and answers on the recommendation for the refusal of a change to the marketing authorisation for Erbitux (cetuximab) European Medicines Agency, (accessed Nov 30, 2010). http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000558/WC500070798.pdf.
3. Fojo T, Grady C How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009, 101:1044-1048.
4. Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:918-927.
5. Gatzemeier U, von Pawel J, Vynnychenko I, et al. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol 2010, published online Dec 20. 10.1016/S1470-2045(10)70278-3.